Literature DB >> 24661580

Impact of periodic selective mebendazole treatment on soil-transmitted helminth infections in Cuban schoolchildren.

Suzanne D van der Werff1,2, Kim Vereecken2, Kim van der Laan1, Maiza Campos Ponce1, Raquel Junco Díaz3, Fidel A Núñez4, Lázara Rojas Rivero4, Mariano Bonet Gorbea3, Katja Polman1,2.   

Abstract

OBJECTIVE: To evaluate the impact of periodic selective treatment with 500 mg mebendazole on soil-transmitted helminth (STH) infections in Cuban schoolchildren.
METHODS: We followed up a cohort of 268 STH-positive schoolchildren, aged 5-14 years at baseline, at six-month intervals for two years and a final follow-up after three years. Kato-Katz stool examination was used to detect infections with Ascaris lumbricoides, Trichuris trichiura and hookworm. Common risk factors related to STHs were assessed by parental questionnaire.
RESULTS: A significant reduction in the number of STH infections was obtained after three years with the highest reduction for T. trichiura (87.8%) and the lowest for hookworm (57.9%). After six months, cure rates (CRs) were 76.9% for A. lumbricoides, 67.4% for T. trichiura and 44.4% for hookworm. After two treatment rounds, more than 75% of all STH-positive children at baseline were cured, but with important differences between STH species (95.2% for A. lumbricoides, 80.5% for T. trichiura and 76.5% for hookworm). At the end of the study, these cumulative CRs were almost 100% for all three STHs. Risk factors for STHs were sex, sanitary disposal and habit of playing in the soil.
CONCLUSIONS: Our results indicate that periodic selective treatment with 500 mg mebendazole is effective in reducing the number of STH infections in Cuban schoolchildren. Although important differences were found between helminth species, two rounds of treatment appeared sufficient to obtain substantial reductions.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Cuba; efectividad; effectiveness; efficacité; géohelminthes; helmintos transmitidos por helmintos transmitidos por el suelo; mebendazol; mebendazole; mébendazole; niños escolares; schoolchildren; selective treatment; soil-transmitted helminths; traitement sélectif; tratamiento selectivo; écoliers

Year:  2014        PMID: 24661580     DOI: 10.1111/tmi.12290

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  5 in total

1.  Prevalence of Giardiaduodenalis among children from a central region of Cuba: molecular characterization and associated risk factors.

Authors:  Luis Jerez Puebla; Fidel A Núñez; Alexey Brito García; Lázara Rojas Rivero; Irais Atencio Millán; Raúl Cordoví Prado
Journal:  J Parasit Dis       Date:  2016-07-15

2.  Increased Prevalence of Cestode Infection Associated with History of Deworming among Primary School Children in Ethiopia.

Authors:  Nader Mohamed; Anna Muse; Moges Wordofa; Dessie Abera; Abiyot Mesfin; Mistire Wolde; Kassu Desta; Aster Tsegaye; Bineyam Taye
Journal:  Am J Trop Med Hyg       Date:  2019-09       Impact factor: 2.345

Review 3.  Preventive chemotherapy in one year reduces by over 80% the number of individuals with soil-transmitted helminthiases causing morbidity: results from meta-analysis.

Authors:  Chiara Marocco; Mathieu Bangert; Serene A Joseph; Christopher Fitzpatrick; Antonio Montresor
Journal:  Trans R Soc Trop Med Hyg       Date:  2017-01-01       Impact factor: 2.184

4.  The impact of an 8-year mass drug administration programme on prevalence, intensity and co-infections of soil-transmitted helminthiases in Burundi.

Authors:  Giuseppina Ortu; Mohamad Assoum; Udo Wittmann; Sarah Knowles; Michelle Clements; Onésime Ndayishimiye; Maria-Gloria Basáñez; Colleen Lau; Archie Clements; Alan Fenwick; Ricardo J Soares Magalhaes
Journal:  Parasit Vectors       Date:  2016-09-22       Impact factor: 3.876

5.  Efficacy and Safety of a Single-Dose Mebendazole 500 mg Chewable, Rapidly-Disintegrating Tablet for Ascaris lumbricoides and Trichuris trichiura Infection Treatment in Pediatric Patients: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study.

Authors:  Steven A Silber; Ermias Diro; Netsanet Workneh; Zeleke Mekonnen; Bruno Levecke; Peter Steinmann; Irenee Umulisa; Hailemaryam Alemu; Benny Baeten; Marc Engelen; Peter Hu; Andrew Friedman; Alan Baseman; Joseph Mrus
Journal:  Am J Trop Med Hyg       Date:  2017-08-31       Impact factor: 2.345

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.